

**SOCS1 Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP8790a****Specification**

---

**SOCS1 Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [O15524](#)**SOCS1 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 8651**Other Names**

Suppressor of cytokine signaling 1, SOCS-1, JAK-binding protein, JAB, STAT-induced STAT inhibitor 1, SSI-1, Tec-interacting protein 3, TIP-3, SOCS1, SSI1, TIP3

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP8790a](/products/AP8790a) was selected from the N-term region of human SOCS1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SOCS1 Antibody (N-term) Blocking Peptide - Protein Information****Name** SOCS1**Synonyms** SSI1, TIP3 {ECO:0000303|PubMed:9341160}**Function**

Essential negative regulator of type I and type II interferon (IFN) signaling, as well as that of other cytokines, including IL2, IL4, IL6 and leukemia inhibitory factor (LIF) (PubMed: [32499645](http://www.uniprot.org/citations/32499645), PubMed: [33087723](http://www.uniprot.org/citations/33087723)). Downregulates cytokine signaling by inhibiting the JAK/STAT signaling pathway. Acts by binding to JAK proteins and to IFNGR1 and inhibiting their kinase activity. In vitro, suppresses Tec protein-tyrosine activity (PubMed: [9341160](http://www.uniprot.org/citations/9341160)). Regulates IFN-gamma (IFNG)- mediated sensory neuron survival (By similarity). Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box

protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:<a href="http://www.uniprot.org/citations/11278610" target="\_blank">11278610</a>, PubMed:<a href="http://www.uniprot.org/citations/11313480" target="\_blank">11313480</a>).

**Cellular Location**

Nucleus. Cytoplasmic vesicle. Note=Detected in perinuclear cytoplasmic vesicles upon interaction with FGFR3

**Tissue Location**

Expressed in all tissues with high expression in spleen, small intestine and peripheral blood leukocytes

**SOCS1 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**SOCS1 Antibody (N-term) Blocking Peptide - Images****SOCS1 Antibody (N-term) Blocking Peptide - Background**

SOCS1 is a member of the STAT-induced STAT inhibitor (SSI), also known as suppressor of cytokine signaling(SOCS), family. SSI family members are cytokine-inducible negative regulators of cytokine signaling.

**SOCS1 Antibody (N-term) Blocking Peptide - References**

Starr,R.,et.al., Nature 387 (6636), 917-921 (1997)Minamoto,S., et.al., Biochem. Biophys. Res. Commun. 237 (1), 79-83 (1997)